Skip to main content
Erschienen in: Die Onkologie 8/2023

05.07.2023 | Tumorschmerz | CME

Medikamentöse Schmerztherapie bei Patienten mit Tumorerkrankungen

verfasst von: Anke Mütherig, Dr. rer. medic. Gesine Scheffler, PD Dr. med. Ulrich S. Schuler

Erschienen in: Die Onkologie | Ausgabe 8/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die medikamentöse Schmerztherapie bei Tumorerkrankungen basiert auf Leitlinienempfehlungen, die bei unterschiedlicher Gewichtung der Evidenz nicht in allen Punkten übereinstimmen. Der vorliegende Beitrag diskutiert aktuelle Fragen, unter anderem die abnehmende Bedeutung des Stufenschemas der Weltgesundheitsorganisation (WHO), dessen Unterscheidung zwischen Stufe 2 und 3 zunehmend hinterfragt wird. Risiken von Nichtopioidanalgetika wie Paracetamol und nichtsteroidalen Antirheumatika, insbesondere in älteren Populationen, werden diskutiert. Paracetamol kann eventuell die Wirksamkeit von Immuntherapien vermindern. Es werden Überlegungen zur Schmerztherapie via Sonde angestellt. Empfehlungen zur Behandlung episodischer Schmerzen und zur Umstellung zwischen verschiedenen Opioiden sowie einige relevante Wechselwirkungen werden besprochen.
Literatur
2.
Zurück zum Zitat Caraceni A, Hanks G et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68CrossRefPubMed Caraceni A, Hanks G et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68CrossRefPubMed
3.
Zurück zum Zitat Mawatari H, Shinjo T et al (2022) Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese society of palliative medicine. J Palliat Med 25:1095–1114CrossRefPubMed Mawatari H, Shinjo T et al (2022) Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese society of palliative medicine. J Palliat Med 25:1095–1114CrossRefPubMed
4.
Zurück zum Zitat Paice JA, Bohlke K et al (2023) Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol 41:914–930CrossRefPubMed Paice JA, Bohlke K et al (2023) Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol 41:914–930CrossRefPubMed
5.
Zurück zum Zitat WHO (2018) WHO guidelines for the pharmacological and Radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization, Geneva WHO (2018) WHO guidelines for the pharmacological and Radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization, Geneva
6.
Zurück zum Zitat Deandrea S, Montanari M et al (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985–1991CrossRefPubMedPubMedCentral Deandrea S, Montanari M et al (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985–1991CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Roberto A, Greco MT et al (2022) Living systematic review to assess the analgesic undertreatment in cancer patients. Pain Pract 22:487–496CrossRefPubMed Roberto A, Greco MT et al (2022) Living systematic review to assess the analgesic undertreatment in cancer patients. Pain Pract 22:487–496CrossRefPubMed
8.
Zurück zum Zitat Snijders Ra H, Brom L et al (2023) Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis. Cancers 15(3):591CrossRefPubMedPubMedCentral Snijders Ra H, Brom L et al (2023) Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis. Cancers 15(3):591CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Radbruch L, Loick G et al (1999) Validation of the German version of the brief pain inventory. J Pain Symptom Manage 18:180–187CrossRefPubMed Radbruch L, Loick G et al (1999) Validation of the German version of the brief pain inventory. J Pain Symptom Manage 18:180–187CrossRefPubMed
10.
Zurück zum Zitat Butow P, Sharpe L (2013) The impact of communication on adherence in pain management. Pain 154(Suppl 1):S101–s107CrossRefPubMed Butow P, Sharpe L (2013) The impact of communication on adherence in pain management. Pain 154(Suppl 1):S101–s107CrossRefPubMed
11.
Zurück zum Zitat Chapman EJ, Edwards Z et al (2020) Practice review: evidence-based and effective management of pain in patients with advanced cancer. Palliat Med 34:444–453CrossRefPubMed Chapman EJ, Edwards Z et al (2020) Practice review: evidence-based and effective management of pain in patients with advanced cancer. Palliat Med 34:444–453CrossRefPubMed
12.
Zurück zum Zitat Meldrum M (2005) The ladder and the clock: cancer pain and public policy at the end of the twentieth century. J Pain Symptom Manage 29:41–54CrossRefPubMed Meldrum M (2005) The ladder and the clock: cancer pain and public policy at the end of the twentieth century. J Pain Symptom Manage 29:41–54CrossRefPubMed
13.
Zurück zum Zitat Hasenfuß GG, Jung N, Alt-Epping B, Galle J, Koop H, Grandt D, Rémi C (2021) Klug entscheiden: No-Gos bei Medikamentenkombis. Dtsch Ärztebl 118:A–630 Hasenfuß GG, Jung N, Alt-Epping B, Galle J, Koop H, Grandt D, Rémi C (2021) Klug entscheiden: No-Gos bei Medikamentenkombis. Dtsch Ärztebl 118:A–630
16.
Zurück zum Zitat Bandieri E, Romero M et al (2016) Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 34:436–442CrossRefPubMed Bandieri E, Romero M et al (2016) Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 34:436–442CrossRefPubMed
17.
Zurück zum Zitat Fallon M, Dierberger K et al (2022) An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer. Ann Oncol 33:1296–1303CrossRefPubMed Fallon M, Dierberger K et al (2022) An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer. Ann Oncol 33:1296–1303CrossRefPubMed
18.
Zurück zum Zitat Maltoni M, Scarpi E et al (2005) A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 13:888–894CrossRefPubMed Maltoni M, Scarpi E et al (2005) A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 13:888–894CrossRefPubMed
19.
Zurück zum Zitat Crush J, Levy N et al (2022) Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labelling opioids as weak or strong. Br J Anaesth 129:137–142CrossRefPubMed Crush J, Levy N et al (2022) Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labelling opioids as weak or strong. Br J Anaesth 129:137–142CrossRefPubMed
20.
Zurück zum Zitat Tassinari D, Drudi F et al (2011) The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain: a systematic review. Palliat Med 25:410–423CrossRefPubMed Tassinari D, Drudi F et al (2011) The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain: a systematic review. Palliat Med 25:410–423CrossRefPubMed
21.
Zurück zum Zitat Gourlay GK, Cherry DA et al (1986) A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25:297–312CrossRefPubMed Gourlay GK, Cherry DA et al (1986) A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25:297–312CrossRefPubMed
23.
Zurück zum Zitat Duarte FCN, Ferraro L et al (2021) A randomized controlled trial evaluating the analgesic effect of the combination of methadone with morphine for cancer related pain. Clin J Pain 37:664–668CrossRefPubMed Duarte FCN, Ferraro L et al (2021) A randomized controlled trial evaluating the analgesic effect of the combination of methadone with morphine for cancer related pain. Clin J Pain 37:664–668CrossRefPubMed
25.
Zurück zum Zitat Pergolizzi J, Aloisi AM et al (2010) Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 10:428–450CrossRefPubMed Pergolizzi J, Aloisi AM et al (2010) Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 10:428–450CrossRefPubMed
26.
Zurück zum Zitat Thakerar A, Dines-Muntaner S et al (2020) Parecoxib as an adjunct therapy for the treatment of refractory non-surgical cancer pain. J Oncol Pharm Pract 26:1407–1414CrossRefPubMed Thakerar A, Dines-Muntaner S et al (2020) Parecoxib as an adjunct therapy for the treatment of refractory non-surgical cancer pain. J Oncol Pharm Pract 26:1407–1414CrossRefPubMed
28.
Zurück zum Zitat Balanaser M, Carley M et al (2023) Combination pharmacotherapy for the treatment of neuropathic pain in adults: systematic review and meta-analysis. Pain 164:230–251CrossRefPubMed Balanaser M, Carley M et al (2023) Combination pharmacotherapy for the treatment of neuropathic pain in adults: systematic review and meta-analysis. Pain 164:230–251CrossRefPubMed
29.
Zurück zum Zitat Dou Z, Jiang Z et al (2017) Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy. Asia Pac J Clin Oncol 13:e57–e64CrossRefPubMed Dou Z, Jiang Z et al (2017) Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy. Asia Pac J Clin Oncol 13:e57–e64CrossRefPubMed
30.
Zurück zum Zitat To J, Davis M et al (2023) MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events. Support Care Cancer 31:202CrossRefPubMed To J, Davis M et al (2023) MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events. Support Care Cancer 31:202CrossRefPubMed
31.
Zurück zum Zitat Currow DC, Clark K et al (2020) A randomized, double-blind, crossover, dose ranging study to determine the optimal dose of oral opioid to treat breakthrough pain for patients with advanced cancer already established on regular opioids. Eur J Pain 24:983–991CrossRefPubMed Currow DC, Clark K et al (2020) A randomized, double-blind, crossover, dose ranging study to determine the optimal dose of oral opioid to treat breakthrough pain for patients with advanced cancer already established on regular opioids. Eur J Pain 24:983–991CrossRefPubMed
32.
Zurück zum Zitat Mercadante S, Adile C et al (2015) Fentanyl Buccal tablet vs. Oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a randomized, crossover, comparison study. J Pain Symptom Manage 50:579–586CrossRefPubMed Mercadante S, Adile C et al (2015) Fentanyl Buccal tablet vs. Oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a randomized, crossover, comparison study. J Pain Symptom Manage 50:579–586CrossRefPubMed
Metadaten
Titel
Medikamentöse Schmerztherapie bei Patienten mit Tumorerkrankungen
verfasst von
Anke Mütherig
Dr. rer. medic. Gesine Scheffler
PD Dr. med. Ulrich S. Schuler
Publikationsdatum
05.07.2023

Weitere Artikel der Ausgabe 8/2023

Die Onkologie 8/2023 Zur Ausgabe